Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug;136(8):1213-9.
doi: 10.1007/s00432-010-0771-5. Epub 2010 Feb 3.

Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma

Dongrong Situ  1 , Hao Long, Peng Lin, Zhihua Zhu, Jiang Wang, Xu Zhang, Zeming Xie, Tiehua Rong
Affiliations

Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma

Dongrong Situ et al. J Cancer Res Clin Oncol. 2010 Aug.

Abstract

Purpose: Expression of CD44 and its variants has been shown to be relevant to tumor progression in various human malignancies. We evaluated the expression of CD44v6 in the primary lesions of stage I non-small cell lung cancer (NSCLC) and correlated the expression level to its prognosis.

Methods: The expression of CD44v6, measured by immunohistochemistry, was assessed in the tumor specimens from 190 patients with stage I NSCLC. Each slide was assigned a score: the average of the score of tumor cells staining multiplied by the score of staining intensity. And depending on the cut-off score based on receiver operating characteristic (ROC) curve analysis, the CD44v6 expression was categorized into high- and low-level groups, which were then correlated directly with the clinical outcomes.

Results: The high expression of CD44v6 was detected more frequently in the squamous cell carcinoma (38 of 71 patients, 53.5%) than in the other types of carcinoma (p < 0.05). The Kaplan-Meier survival curves showed that high level expression of CD44v6 indicated a better post-operative survival (p = 0.006), especially for stage IB disease (p = 0.049) and squamous cell carcinoma (p = 0.029). The multivariate analysis also confirmed that the expression of CD44v6 was an independent prognostic indicator (p = 0.011).

Conclusions: CD44v6 might be correlated with histogenesis of NSCLC, and its decreased expression may be an adverse prognostic indicator for the patients with stage I NSCLC, especially for those with stage IB diseases. Patients of this subgroup might need adjuvant therapy additionally.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Expression of CD44v6 in NSCLC cells (Membranous). a Immunohistochemical staining of squamous cell carcinoma (100×, IHC score:15). b Immunohistochemical staining of adenocarcinoma (100×, IHC score:15). c Immunohistochemical staining of adenocarcinoma (100×, IHC score:3)
Fig. 2
Fig. 2
Receiver operating characteristic (ROC) curve for CD44v6 and the selection of cut-off score
Fig. 3
Fig. 3
Correlation between CD44v6 expression and NSCLC survival regarding pathological stages. a OS for 190 stage I NSCLC patients. b OS for 84 stage IA NSCLC patients. c OS for 106 stage IB NSCLC patients
Fig. 4
Fig. 4
Correlation between CD44v6 expression and NSCLC survival regarding histological types. a OS for 71 squamous cell carcinoma patients. b OS for 60 adenocarcinoma patients. c OS for 39 bronchioalveolar carcinoma patients
See this image and copyright information in PMC

References

    1. ASCO (1997) Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, by the American Society of Clinical Oncology. J Clin Oncol 15(8):2996–3018 - PubMed
    1. Bains MS (1991) Surgical treatment of lung cancer. Chest 100(3):826–837 - PubMed
    1. Carter WG, Wayner EA (1988) Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. J Biol Chem 263(9):4193–4201 - PubMed
    1. Coradini D, Zorzet S, Rossin R et al (2004) Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res 10(14):4822–4830 - PubMed
    1. Dong WG, Sun XM, Yu BP, Luo HS, Yu JP (2003) Role of VEGF and CD44v6 in differentiating benign from malignant ascites. World J Gastroenterol 9(11):2596–2600 - PMC - PubMed

Publication types

MeSH terms